Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Deffered Revenue (2016 - 2017)

Historic Non-Current Deffered Revenue for Coherus Oncology (CHRS) over the last 5 years, with Q1 2017 value amounting to $725000.0.

  • Coherus Oncology's Non-Current Deffered Revenue fell 9780.12% to $725000.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $725000.0, marking a year-over-year decrease of 9780.12%. This contributed to the annual value of $669000.0 for FY2016, which is 9852.44% down from last year.
  • As of Q1 2017, Coherus Oncology's Non-Current Deffered Revenue stood at $725000.0, which was down 9780.12% from $669000.0 recorded in Q4 2016.
  • In the past 5 years, Coherus Oncology's Non-Current Deffered Revenue registered a high of $45.3 million during Q4 2015, and its lowest value of $595000.0 during Q3 2016.
  • For the 5-year period, Coherus Oncology's Non-Current Deffered Revenue averaged around $27.1 million, with its median value being $33.2 million (2015).
  • As far as peak fluctuations go, Coherus Oncology's Non-Current Deffered Revenue skyrocketed by 3966.81% in 2014, and later tumbled by 9852.44% in 2016.
  • Coherus Oncology's Non-Current Deffered Revenue (Quarter) stood at $28.6 million in 2013, then skyrocketed by 39.67% to $39.9 million in 2014, then rose by 13.63% to $45.3 million in 2015, then tumbled by 98.52% to $669000.0 in 2016, then grew by 8.37% to $725000.0 in 2017.
  • Its Non-Current Deffered Revenue was $725000.0 in Q1 2017, compared to $669000.0 in Q4 2016 and $595000.0 in Q3 2016.